Estelle Torbey
Estelle Torbey has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Annabelle Santos Volgman
Rush Heart Center for Women, Division of Cardiology, Rush University Medical Center, Chicago, IL, USA
1 shared publication - Basem Azab
Department of Internal Medicine, Staten Island University Hospital, Staten Island, NY, USA
1 shared publication - Devika Adusumilli
Department of Internal Medicine, Medical City Hospital , Fort Worth, TX
1 shared publication Georges Abourjaili
Staten Island University Hospital, Department of Medicine, Division of Cardiology, Staten Island
1 shared publication- Homam Alkaied
Staten Island University Hospital, 475 Seaview Ave, Staten Island, NY 10305, USA
1 shared publication - Ian Curnutt
Department of Internal Medicine, Kansas City University College of Osteopathic Medicine, Joplin, MO 64804, USA
1 shared publication
Latest Publications
- Open Access
- 22 July 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (7) , 343
Arrhythmias in Autoimmune Diseases: Immune-Mediated Mechanisms and Management
Autoimmune diseases substantially increase the risk of atrial and ventricular arrhythmias and sudden cardiac death through shared immune-mediated mechanisms. Pro-inflammatory cytokines, autoantibodies, and progressive myocardial fibrosis disrupt ion channel function, impair conduction, and create re-entrant substrates. Across systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis (SSc), these pathways manifest as atrial fibrillation, ventricular arrhythmias, conduction disease, and heightened arrhythmic mortality. Anti Ro/SSA antibodies, in particular, contribute to QT prolongation and atrioventricular (AV) block, while cytokines such as TNF α, IL 1β, and IL 6 remodel electrophysiological properties and promote fibrosis. Advanced cardiac imaging, especially cardiac magnetic resonance (CMR), detects inflammation and fibrosis even when ejection fraction is preserved, enabling earlier intervention. Management requires a dual approach: standard arrhythmia therapies alongside aggressive control of systemic inflammation with disease-specific immunosuppression. Despite growing evidence, major gaps remain, including the absence of randomized trials targeting immune-driven arrhythmias and the need for integrated risk models incorporating inflammatory biomarkers.
- 22 July 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (7) , 343
Open AccessArrhythmias in Autoimmune Diseases: Immune-Mediated Mechanisms and Management
Autoimmune diseases substantially increase the risk of atrial and ventricular arrhythmias and sudden cardiac death through shared immune-mediated mechanisms. Pro-inflammatory cytokines, autoantibodies, and progressive myocardial fibrosis disrupt ion channel function, impair conduction, and create re-entrant substrates. Across systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis (SSc), these pathways manifest as atrial fibrillation, ventricular arrhythmias, conduction disease, and heightened arrhythmic mortality. Anti Ro/SSA antibodies, in particular, contribute to QT prolongation and atrioventricular (AV) block, while cytokines such as TNF α, IL 1β, and IL 6 remodel electrophysiological properties and promote fibrosis. Advanced cardiac imaging, especially cardiac magnetic resonance (CMR), detects inflammation and fibrosis even when ejection fraction is preserved, enabling earlier intervention. Management requires a dual approach: standard arrhythmia therapies alongside aggressive control of systemic inflammation with disease-specific immunosuppression. Despite growing evidence, major gaps remain, including the absence of randomized trials targeting immune-driven arrhythmias and the need for integrated risk models incorporating inflammatory biomarkers.
- Open Access
- 16 April 2013
- Published by Springer Nature in Annals of Surgical Innovation and Research
- Vol. 7 (1) , 4
Gastroduodenal artery aneurysm, diagnosis, clinical presentation and management: a concise review
Gastroduodenal artery (GDA) aneurysms are rare but a potentially fatal condition if rupture occurs. They represent about 1.5% of all visceral artery (VAA) aneurysms and are divided into true and pseudoaneurysms depending on the etiologic factors underlying their development. Atherosclerosis and pancreatitis are the two most common risk factors. Making the diagnosis can be complex and often requires the use of Computed Tomography and angiography. The later adds the advantage of being a therapeutic option to prevent or stop bleeding. If this fails, surgery is still regarded as the standard for accomplishing a definite treatment.
- 16 April 2013
- Published by Springer Nature in Annals of Surgical Innovation and Research
- Vol. 7 (1) , 4
Open AccessGastroduodenal artery aneurysm, diagnosis, clinical presentation and management: a concise review
Gastroduodenal artery (GDA) aneurysms are rare but a potentially fatal condition if rupture occurs. They represent about 1.5% of all visceral artery (VAA) aneurysms and are divided into true and pseudoaneurysms depending on the etiologic factors underlying their development. Atherosclerosis and pancreatitis are the two most common risk factors. Making the diagnosis can be complex and often requires the use of Computed Tomography and angiography. The later adds the advantage of being a therapeutic option to prevent or stop bleeding. If this fails, surgery is still regarded as the standard for accomplishing a definite treatment.
- 1 January 2012
- Vol. 17 (4) , 248-50
Hemolytic anemia following mitral valve repair: A case presentation and literature review.
Hemolytic anemia is a known complication after valve replacement, but the incidence of hemolysis following valve repair is unknown. A case involving mitral annuloplasty complicated by hemolytic anemia, which resolved after replacement of the valve, is presented. Only 70 cases of hemolysis after mitral valve repair have been reported in the literature. In nearly all of these cases, replacement or rerepair of the valve was the definitive treatment for hemolysis.
- 1 January 2012
- Vol. 17 (4) , 248-50
Hemolytic anemia following mitral valve repair: A case presentation and literature review.
Hemolytic anemia is a known complication after valve replacement, but the incidence of hemolysis following valve repair is unknown. A case involving mitral annuloplasty complicated by hemolytic anemia, which resolved after replacement of the valve, is presented. Only 70 cases of hemolysis after mitral valve repair have been reported in the literature. In nearly all of these cases, replacement or rerepair of the valve was the definitive treatment for hemolysis.